指南与共识胸部病理细胞病理与分子病理

肺癌免疫检查点抑制剂治疗选择中PD-L1与TMB检测指南

Programmed Death Ligand-1 and Tumor Mutation Burden Testing of Patients With Lung Cancer for Selection of Immune Checkpoint Inhibitor Therapies: Guideline From the College of American Pathologists, Association for Molecular Pathology, International Association for the Study of Lung Cancer, Pulmonary Pathology Society, and LUNGevity Foundation.
指南 / 共识 · Arch Pathol Lab Med · 2024-01-01

美国病理学家学会等五家机构联合制定循证指南,针对晚期非小细胞肺癌患者PD-L1表达与肿瘤突变负荷检测的8个关键问题系统检索文献,采用GRADE方法形成6条推荐声明,以规范免疫检查点抑制剂治疗的生物标志物检测。

要点

  • 指南针对晚期非小细胞肺癌PD-L1与TMB检测提出6条循证推荐。
  • 采用GRADE方法基于证据质量与关键判断形成推荐。
  • 旨在减少检测方法学差异带来的实践不确定性。

核心结论

  • 指南总结了PD-L1表达与TMB检测用于晚期非小细胞肺癌免疫检查点抑制剂治疗选择的现状与障碍,并给出循证推荐。

研究设计与样本

  • 美国病理学家学会召集非小细胞肺癌与生物标志物检测专家组,按美国国家医学院可信临床实践指南标准制定。
  • 系统文献综述针对8个关键问题,采用GRADE方法及证据到决策框架形成推荐。

主要发现

  • 共形成6条推荐声明。

关键数值与推荐

  • 推荐声明共6条,具体条款未在摘要中列出。

临床怎么用

  • 用于指导晚期非小细胞肺癌患者免疫检查点抑制剂治疗选择中的PD-L1与TMB检测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT.—: Rapid advancements in the understanding and manipulation of tumor-immune interactions have led to the approval of immune therapies for patients with non-small cell lung cancer. Certain immune checkpoint inhibitor therapies require the use of companion diagnostics, but methodologic variability has led to uncertainty around test selection and implementation in practice. OBJECTIVE.—: To develop evidence-based guideline recommendations for the testing of immunotherapy/immunomodulatory biomarkers, including programmed death ligand-1 (PD-L1) and tumor mutation burden (TMB), in patients with lung cancer. DESIGN.—: The College of American Pathologists convened a panel of experts in non-small cell lung cancer and biomarker testing to develop evidence-based recommendations in accordance with the standards for trustworthy clinical practice guidelines established by the National Academy of Medicine. A systematic literature review was conducted to address 8 key questions. Using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach, recommendations were created from the available evidence, certainty of that evidence, and key judgments as defined in the GRADE Evidence to Decision framework. RESULTS.—: Six recommendation statements were developed. CONCLUSIONS.—: This guideline summarizes the current understanding and hurdles associated with the use of PD-L1 expression and TMB testing for immune checkpoint inhibitor therapy selection in patients with advanced non-small cell lung cancer and presents evidence-based recommendations for PD-L1 and TMB testing in the clinical setting.

来源:Arch Pathol Lab Med,查看原文。版权归原作者所有。

引用

  1. Sholl LM, Awad M, Basu Roy U, et al. Programmed Death Ligand-1 and Tumor Mutation Burden Testing of Patients With Lung Cancer for Selection of Immune Checkpoint Inhibitor Therapies: Guideline From the College of American Pathologists, Association for Molecular Pathology, International Association for the Study of Lung Cancer, Pulmonary Pathology Society, and LUNGevity Foundation. Arch Pathol Lab Med. 2024. PMID: 38625026. doi:10.5858/arpa.2023-0536-CP

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。